BOKE Bio Gets ￥10M In Pre-A Round

According to PEdaily.cn, BOKE Bioscience Co., Ltd. ("BOKE Bio") recently announced the completion of a Pre-A round of financing worth tens of millions of RMB, led by Jianxing Medical Fund managed by CCB International, with participation from Shenzhen Shangkun Medical Fund. 

The new investment round will enable BOKE Bio to further solidify its position in the domestic market, explore overseas markets, develop new techonologies related to DNA data storage, antibody libraries and generate nucleic acids in line with the GMP standard, so as to strengthen the advantages in the field of high-quality nucleic acid synthesis.

BOKE Bio is an innovator of high-throughput DNA synthesis in China. With the rapid development of precision medicine, gene panels have become important components in application, playing a significant role in ensuring the quality of devices in the medical fields such as reproduction, genetic diseases, tumor diagnosis, tumor early screening, pathogen detection and so on. And gene panels have been widely applied in the optimization screening and detection of plant and animal breeding.

The production, manufacturing and quality control of gene panels have high requirements for nucleic acid synthesis. In recent years, the domestic market has been monopolized by overseas companies. BOKE Bio owns patents of design, synthesis, purification, and quality control of gene panels with completely independent intellectual property rights. Aiming to "finish personalized customization within one week", the performance of BOKE Bio's products has reached or surpassed its international competitors, breaking the monopoly of overseas companies.

BOKE Bio has developed several gene panels based on the new generation sequencing (NGS) and nanopore sequencing for many domestic medical institutions, as well as well-known hospitals and clinical academics at home and abroad. In September 2020, BOKE Bio completed the development and testing of the first full-process chip for human whole-exome sequencing made in China and launched it into the market.

CCB International (Holdings) Limited and its subsidiaries (CCB International) is an investment services flagship which is owned by China Construction Bank Corporation ("CCB"). Its core business is divided into three main areas, namely Pre-IPO, IPO and Post-IPO which in turn form a comprehensive investment services value chain.